Eidos Therapeutics (NASDAQ:EIDX) received a $56.00 price target from equities researchers at BTIG Research in a research report issued to clients and investors on Tuesday, TipRanks reports. The firm presently has a “buy” rating on the stock. BTIG Research’s price objective would suggest a potential upside of 59.09% from the stock’s current price.
EIDX has been the subject of several other reports. ValuEngine cut Eidos Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 2nd. Piper Jaffray Companies initiated coverage on Eidos Therapeutics in a research note on Monday, July 22nd. They set an “overweight” rating and a $55.00 target price for the company. BMO Capital Markets boosted their target price on Eidos Therapeutics to $50.00 and gave the stock an “outperform” rating in a research note on Monday, July 22nd. Finally, Zacks Investment Research raised Eidos Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the stock. Eidos Therapeutics currently has an average rating of “Buy” and a consensus target price of $41.67.
EIDX traded down $0.22 on Tuesday, hitting $35.20. 100,258 shares of the company were exchanged, compared to its average volume of 186,016. Eidos Therapeutics has a twelve month low of $9.03 and a twelve month high of $49.72. The company has a market cap of $1.36 billion, a price-to-earnings ratio of -18.92 and a beta of -1.05. The company has a current ratio of 20.89, a quick ratio of 20.89 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $40.59 and a two-hundred day moving average price of $33.28.
Eidos Therapeutics (NASDAQ:EIDX) last released its earnings results on Thursday, August 1st. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.01). Equities analysts expect that Eidos Therapeutics will post -1.7 EPS for the current year.
In other news, insider Jonathan C. Fox sold 5,000 shares of the company’s stock in a transaction dated Monday, September 16th. The stock was sold at an average price of $45.74, for a total transaction of $228,700.00. Also, insider Uma Sinha sold 2,500 shares of the company’s stock in a transaction dated Wednesday, September 25th. The stock was sold at an average price of $38.41, for a total value of $96,025.00. Insiders have sold a total of 17,500 shares of company stock valued at $698,975 over the last three months. 70.10% of the stock is currently owned by insiders.
Large investors have recently added to or reduced their stakes in the company. Bank of Montreal Can boosted its position in shares of Eidos Therapeutics by 151.8% during the 2nd quarter. Bank of Montreal Can now owns 1,385 shares of the company’s stock worth $43,000 after acquiring an additional 835 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Eidos Therapeutics during the 2nd quarter worth about $125,000. Metropolitan Life Insurance Co NY acquired a new position in shares of Eidos Therapeutics during the 1st quarter worth about $143,000. MetLife Investment Advisors LLC acquired a new position in shares of Eidos Therapeutics during the 1st quarter worth about $198,000. Finally, Strs Ohio boosted its position in shares of Eidos Therapeutics by 457.1% during the 2nd quarter. Strs Ohio now owns 11,700 shares of the company’s stock worth $363,000 after acquiring an additional 9,600 shares in the last quarter. 32.46% of the stock is owned by institutional investors and hedge funds.
About Eidos Therapeutics
Eidos Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on developing drugs to treat diseases caused by transthyretin (TTR) amyloidosis (ATTR). It is developing AG10, an orally-administered small molecule designed to stabilize tetrameric TTR, thereby halting at its outset the series of molecular events that give rise to ATTR.
Further Reading: Bond
Receive News & Ratings for Eidos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eidos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.